UAE Banking Heavyweight Joins NeOnc as Global Brain-Cancer Drug Development Advances

NeOnc said redemption of all outstanding Series A convertible preferred stock eliminated the related potential dilution.

Rhea-AI Summary

NeOnc Technologies Holdings (NASDAQ: NTHI) appointed Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, to its board. The company is pursuing UAE clinical development alongside its U.S. programs.

Both lead candidates have Abu Dhabi investigational drug authorizations. NEO100’s June authorization covers adult Phase 1–2 protocols; pediatric studies require further protocol review. NEO212 completed Phase 1 dose escalation, with potential Phase 2 development subject to ethics approvals and other pre-enrollment conditions.

August topline results from the 24-patient NEO100 Phase 2a study included six-month progression-free survival of 48.9% and median overall survival of 26.09 months. NeOnc priced a $15 million registered direct offering and redeemed all Series A convertible preferred stock without issuing common shares. A November 17 FDA meeting is scheduled for NEO212; the company expects to discuss potential Phase 2 design and regulatory pathways.

9 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point$15 million registered direct offering priced with new and existing institutional investors. 20% of market cap
• Moderate pointNEO100 Phase 2a topline results in 24 patients included six-month progression-free survival of 48.9%.
• Moderate pointAll outstanding Series A convertible preferred stock redeemed; NeOnc said related potential dilution was eliminated without common-share issuance.
• Minor pointNEO100 Phase 2a topline results included median overall survival of 26.09 months.
• Minor pointNEO100’s June Abu Dhabi authorization covers multiple adult development protocols spanning Phase 1 through Phase 2.

4 minor points

• Minor pointNEO212 received UAE authorization and completed Phase 1 dose escalation.
• Minor pointInsider open-market stock purchases followed the NEO100 study results.
• Minor point. Forward-looking: it has not happened yet and may not happen.November 17 FDA meeting for NEO212 scheduled; NeOnc expects discussion of potential Phase 2 design and regulatory pathways.
• Minor point. Forward-looking: it has not happened yet and may not happen.UAE clinical-development expansion is being pursued alongside U.S. programs.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.NEO212 potential Phase 2 development remains subject to applicable ethics approvals and other pre-enrollment conditions.
• Minor point. Forward-looking: it has not happened yet and may not happen.NEO100 pediatric studies remain subject to further protocol review.

Key Figures

FAB total assets: AED 1.41 trillion NEO100 Phase 2a study size: 24 patients Six-month progression-free survival: 48.9% +3 more

FAB total assets

AED 1.41 trillion

As of June 30, 2026

NEO100 Phase 2a study size

24 patients

Study reported in August

Six-month progression-free survival

48.9%

NEO100 Phase 2a study

Median overall survival

26.09 months

NEO100 Phase 2a study

Registered direct offering

$15 million

Involving new and existing institutional investors

FDA meeting

November 17

End-of-Phase 1 Type B meeting for NEO212

Key Terms

investigational new drug authorizations, dose escalation, progression-free survival, median overall survival, +2 more

6 terms

investigational new drug authorizations regulatory

"secured Department of Health – Abu Dhabi investigational new drug authorizations"

Regulatory approvals that allow a company or researcher to begin testing an experimental drug in human clinical trials; they are granted after a submitted application (commonly called an Investigational New Drug or IND application in the U.S.) shows sufficient preclinical safety data, manufacturing information, and proposed clinical protocols for regulators to permit human dosing. An investigational authorization permits clinical trial activity but is not a marketing approval — regulators can place conditions or a clinical hold, and further trial results and reviews are required before the drug can be approved for sale.

dose escalation medical

"NEO212 has also received UAE authorization and completed Phase 1 dose escalation"

Dose escalation is the process of gradually increasing the amount of a treatment or substance over time. In finance, it can refer to slowly raising investments or commitments to manage risk and assess performance. For investors, understanding dose escalation helps gauge how companies or strategies adjust their approaches, which can impact future growth or stability.

progression-free survival medical

"including six-month progression-free survival of 48.9%"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

median overall survival medical

"and median overall survival of 26.09 months"

Median overall survival is the middle point of how long patients live after starting treatment, meaning half live longer and half live shorter. It helps doctors understand how effective a treatment is and gives patients an idea of what to expect about their future.

registered direct offering financial

"it priced a $15 million registered direct offering"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

convertible preferred stock financial

"redemption of all outstanding Series A convertible preferred stock"

Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DENVER, Oct. 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – NeOnc Technologies Holdings (NASDAQ: NTHI) made a powerful leadership move at a pivotal moment in its brain-cancer drug development strategy. The appointment of Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank (FAB), to NeOnc’s Board of Directors.

Alabedin brings more than three decades of international banking and executive experience to a company working to advance investigational therapies and expand its presence in the United Arab Emirates. FAB reported AED 1.41 trillion in total assets as of June 30, 2026, underscoring the scale of the financial institution from which NeOnc is drawing its new board-level expertise.

The significance extends beyond a routine board appointment. Alabedin’s background in financial governance, institutional banking and international business development could be particularly relevant as NeOnc pursues a multinational clinical-development strategy. Advancing investigational therapies across jurisdictions requires more than promising laboratory science: it can involve coordinating regulatory requirements, clinical sites, manufacturing, specialist investigators, financing and partnerships across different healthcare systems. Alabedin’s experience may help NeOnc navigate those commercial and institutional complexities as it seeks to turn regulatory progress into clinical execution.

The timing is particularly notable because CEO Amir F. Heshmatpour is scheduled to speak at the Abu Dhabi Future Health Summit 2026, October 20–22, at the ADNEC Centre. On October 22, he is expected to participate in the panel “The Investment Lens: Banking on Prediction,” discussing how capital, precision medicine and international collaboration can help move promising science through clinical development. The summit brings together healthcare leaders, policymakers, researchers and investors in one top destinations for next-generation wealth, reflecting Abu Dhabi’s wider ambition to connect scientific innovation with funding and real-world healthcare implementation. Heshmatpour emphasized the importance of financing and scientific rigor, saying: “For patients and families facing devastating brain cancers, the urgency is real. Our responsibility is to match that urgency with rigorous science and the capital needed to move clinical development forward.”

NeOnc’s UAE strategy is significant because multinational clinical research can help companies broaden access to investigators and patient populations, develop operational relationships across regions and evaluate whether promising therapies can advance through different regulatory pathways. When properly designed and coordinated, international programs can also support recruitment, diversify clinical-site participation and provide experience with different healthcare systems. These benefits are not automatic: trials must follow consistent protocols, appropriate ethics reviews, reliable data standards and jurisdiction-specific requirements. Results from one country do not independently establish a treatment’s effectiveness elsewhere, but building a coordinated international development network can create additional options for a clinical-stage company pursuing complex central nervous system cancers.

Abu Dhabi is seeking to establish itself as a hub for health research, precision medicine, biotechnology and international clinical collaboration. Its Department of Health oversees clinical research approvals, while the emirate has been developing partnerships, research infrastructure and investment initiatives intended to attract life-sciences companies. For NeOnc, the UAE offers a potential platform for regional collaboration and clinical development alongside its U.S. programs. The company has also described NuroMENA as a vehicle for building Middle Eastern relationships. Alabedin’s international banking and institutional experience could be useful as NeOnc evaluates partnerships, capital requirements and the financial structures needed to support this expansion, although any specific future financing or partnership remains unconfirmed.

NeOnc has already secured Department of Health – Abu Dhabi investigational new drug authorizations for both lead candidates. NEO100’s June authorization covers multiple adult development protocols spanning Phase 1 through Phase 2, along with pediatric studies subject to further protocol review. NEO212 has also received UAE authorization and completed Phase 1 dose escalation, positioning it for potential Phase 2 development subject to applicable ethics approvals and other pre-enrollment conditions.

The company’s recent clinical and financial developments add another layer to the story. In August, NeOnc reported topline results from its 24-patient NEO100 Phase 2a study, including six-month progression-free survival of 48.9% and median overall survival of 26.09 months.

The study results were further supported by insider open-market stock purchases following the results, and it priced a $15 million registered direct offering involving new and existing institutional investors.

NeOnc also announced the redemption of all outstanding Series A convertible preferred stock, saying the move eliminated the related potential dilution without issuing common shares.

The next major scheduled regulatory milestone is the November 17 FDA End-of-Phase 1 Type B meeting for NEO212, where the company expects to discuss potential Phase 2 trial design, patient population, endpoints and regulatory pathways.

About 24/7 Market News

In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who joined NeOnc Technologies Holdings’ board of directors?

Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, joined NeOnc’s board. He brings more than three decades of international banking and executive experience.

What did NeOnc’s NEO100 Phase 2a study report?

The 24-patient NEO100 Phase 2a study reported six-month progression-free survival of 48.9% and median overall survival of 26.09 months. These topline results were reported in August.

What does NeOnc expect to discuss at the NEO212 FDA meeting?

NeOnc expects to discuss potential Phase 2 trial design, patient population, endpoints and regulatory pathways at the November 17 FDA End-of-Phase 1 Type B meeting for NEO212.